These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Etiology, Treatment Patterns, and Outcomes for Choroidal Neovascularization in the Pediatric Population: An Intelligent Research in Sight (IRIS®) Registry Study. Finn AP; Fujino D; Lum F; Rao P Ophthalmol Retina; 2022 Feb; 6(2):130-138. PubMed ID: 34091079 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal Antivascular Endothelial Growth Factor Treatment for Inflammatory Choroidal Neovascularization in Noninfectious Uveitis. Woronkowicz M; Niederer R; Lightman S; Tomkins-Netzer O Am J Ophthalmol; 2022 Apr; 236():281-287. PubMed ID: 34289337 [TBL] [Abstract][Full Text] [Related]
4. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization. Ahn SJ; Park KH; Woo SJ Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418 [TBL] [Abstract][Full Text] [Related]
5. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554 [TBL] [Abstract][Full Text] [Related]
6. Treatment of choroidal neovascularization using intravitreal bevacizumab. Pedersen R; Soliman W; Lund-Andersen H; Larsen M Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Yang HS; Kim JG; Kim JT; Joe SG Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429 [TBL] [Abstract][Full Text] [Related]
9. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization. Kang HM; Koh HJ Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study. Iacono P; Battaglia Parodi M; La Spina C; Bandello F Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553 [TBL] [Abstract][Full Text] [Related]
15. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Ng DS; Kwok AK; Tong JM; Chan CW; Li WW Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J; Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Chan WM; Lai TY; Liu DT; Lam DS Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238 [TBL] [Abstract][Full Text] [Related]
20. Etiology and treatment of choroidal neovascularization in pediatric patients. Barth T; Zeman F; Helbig H; Oberacher-Velten I Eur J Ophthalmol; 2016 Aug; 26(5):388-93. PubMed ID: 27375068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]